Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder

References

• Faraone SV, Sergeant JA, Gilberg C et al. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2, 104–113 (2003).
   PubMedGoogle Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition. Text Revision (DSM-IV-TR). American Psychiatric Press, WA, USA (2000).
   Google Scholar
• Laufer MW, Denhoff E. Hyperkinetic behavior syndrome in children. J. Pediatr. 50, 463–474 (1957).
   PubMed Web of Science ®Google Scholar
• Faraone SV, Biederman J, Spencer T et al. Attention-deficit/hyperactivity disorder in adults: an overview. Biol. Psychiatry 48, 9–20 (2000).
   PubMed Web of Science ®Google Scholar
• Murphy K, Barkley RA. Attention deficit hyperactivity disorder adults: comorbidities and adaptive impairments. Comp. Psychiatry 37, 393–401 (1996).
   PubMed Web of Science ®Google Scholar
• Murphy K, Barkley RA. Prevalence of DSM-IV symptoms of ADHD in adult licensed drivers; implications for clinical diagnosis. J. Atten. Disorders 1, 147–161 (1996).
   Google Scholar
• Barkley RA, Fischer M, Smallish L, Fletcher K. The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J. Abnorm. Psychol. 111, 279–289 (2002).
   PubMed Web of Science ®Google Scholar
• Kessler RC. Prevalence of adult ADHD in the United States; results from the national comorbidity survey replication. Proceedings of the 157th Annual Meeting of the American Psychiatric Association. NY, USA (2004).
   Google Scholar
• Wilens TE, Biederman J, Spencer TJ. Attention deficit/hyperactivity disorder across the lifespan. Ann. Rev. Med. 53, 113–131 (2002).
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics. Subcommittee on Attention-Deficit/Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 108, 1033–1044 (2001).
   PubMed Web of Science ®Google Scholar
• Greenhill LL, Halperin JM, Abikoff H. Stimulant medication. J. Am. Acad. Child Adolesc. Psychiatry 38, 503–512 (1999).
   PubMed Web of Science ®Google Scholar
• Connor DF, Steingard RJ. New formulations of stimulants for attention-deficit/hyperactivity disorder; therapeutic potential. CNS Drugs 18, 1011–1030 (2004).
   PubMed Web of Science ®Google Scholar
• Pataki CS, Feinberg DT, McGough JJ. New drugs for the treatment of attention-deficit/hyperactivity disorder. Expert Opin. Emerg. Drugs 9, 293–302 (2004).
   PubMedGoogle Scholar
• Lyseng-Williamson KA, Keating GM. Extended-release methylphenidate (Ritalin LA). Drugs 62, 2251–2259 (2002).
   PubMed Web of Science ®Google Scholar
• Wigal S, Swanson JM, Feifel D et al. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 43, 1406–1414 (2004).
   PubMed Web of Science ®Google Scholar
• Weiss M, Wasdell M, Patin J. A post hoc analysis of d-threo-methylphenidate hydrochloride (Focalin®) versus d,l-threo-methylphenidate hydrochloride (Ritalin®). J. Am. Acad. Child Adolesc. Psychiatry 43, 1415–1421 (2004).
   PubMed Web of Science ®Google Scholar
• Quinn D, Wigal S, Swanson J et al. Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 43, 1422–1429 (2004).
   PubMed Web of Science ®Google Scholar
• Markowitz JS, Straughn AB, Patrick KS. Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: methylphenidate formulations. Pharmacotherapy 23, 1281–1299 (2003).
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang GJ, Fowler JS et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am. J. Psychiatry155, 1325–1331 (1998).
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang GJ, Fowler JS et al. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine; therapeutic mechanisms. Synapse 48, 181–187 (2002).
   Google Scholar
• Ruskin DN, Berstrom DA, Shenker A, Freeman LE, Black D, Walters JR. Drugs used in the treatment of attention-deficit/hyperactivity disorder affect postsynaptic firing rate and oscillation without preferential dopamine autoreceptor action. Biol. Psychiatry 49, 340–350 (2001).
   Google Scholar
• Volkow ND, Wang GJ, Fowler JS et al. Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. Am. J. Psychiatry 161, 1173–1180 (2004).
   PubMed Web of Science ®Google Scholar
• Sheldon RA. Chirotechnology: Industrial Synthesis of Optimally Active Compounds. Marcel Dekker, NY, USA (1993).
   Google Scholar
• Thall E. When drug molecules look in the mirror. J. Chem. Educ. 73, 481–484 (1996).
   Web of Science ®Google Scholar
• Hutt AJ, Tan SC. Drug chirality and its significance. Drugs 52(Suppl. 5), 1–12 (1996).
   PubMedGoogle Scholar
• Davids E, Zhang K, Tarazi FI, Baldessarini RJ. Stereoselective effects of methylphenidate on motor hyperactivity in juvenile rats induced by neonatal 6-hydroxydopamine lesioning. Psychopharmacol. 160, 92–98 (2002).
   PubMed Web of Science ®Google Scholar
• Teo SK, Stirling DI, Thomas SD, Khetani VD. Neurobehavioral effects of racemic threo-methylphenidate and its D and L enantiomers in rats. Pharmacol. Biochem. Behav. 74, 747–754 (2003).
   PubMed Web of Science ®Google Scholar
• Aoyama T, Kotaki H, Sawada Y, Iga T. Stereospecific distribution of methylphenidate enantiomers in rat brain: specific binding to dopamine re-uptake sites. Pharmaceutical Res. 11, 407–411 (1994).
   Google Scholar
• Ding YS, Fowler JS, Volkow ND et al. Chiral drugs: comparison of the pharmacokinetics of [11C]d-threo and l-threo-methylphenidate in the human and baboon brain. Psychopharmacol. 131, 71–78 (1997).
   PubMed Web of Science ®Google Scholar
• Ding YS, Gatley SJ, Panayotis K et al. Brain kinetics of methylphenidate (Ritalin®) enantiomers after oral administration. Synapse 53, 168–175 (2004).
   PubMed Web of Science ®Google Scholar
• Lopez F, Muniz R, Pestreich L, Liu F, Jiang H, Agoropoulou C. Extended-release dexmethylphenidate: efficacy and safety in children with attention-deficit/hyperactivity disorder. J. Dev. Behavior. Ped. 25, 379 (2004).
   Google Scholar
• Silva R, Muniz R, Pestreich L et al. Efficacy and safety of extended-release dexmethylphenidate in children with ADHD. Proceedings of the 45th Annual NCDEU Meeting. FL, USA. (2005).
   Google Scholar
• Spencer T, Adler L, McGough J. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Proceedings of the 157th Annual Meeting of the American Psychiatric Association. NY, USA (2004).
   Google Scholar